Chengdu Sheng Nuo Biotec Co.,Ltd.(688117),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688117 Chengdu Sheng Nuo Biotec Co.,Ltd.

Closed 12-12 15:00:00

41.69

+0.84

+2.06%

High41.80	Low40.40	Vol4.86M
Open40.85	D1 Closing40.85	Amplitude3.43%
Mkt Cap6.55B	Tradable Cap6.55B	Total Shares157.00M
T/O200.00M	T/O Rate3.09%	Tradable Shares157.00M
P/B6.36	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688117","market":"SH","secType":"STK","nameCN":"Chengdu Sheng Nuo Biotec Co.,Ltd.","latestPrice":41.69,"timestamp":1765522800000,"preClose":40.85,"halted":0,"volume":4857762,"delay":0,"changeRate":0.0206,"floatShares":157000000,"shares":157000000,"eps":0.7631,"marketStatus":"Closed","change":0.84,"latestTime":"12-12 15:00:00","open":40.85,"high":41.8,"low":40.4,"amount":200000000,"amplitude":0.0343,"askPrice":41.69,"askSize":13,"bidPrice":41.68,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.7631,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":40.85,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":44.94,"lowLimit":36.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":157385978,"isCdr":false,"pbRate":6.36,"roa":"--","peRate":54.63242,"roe":"12.94%","epsLYR":0.45,"committee":0.540107,"marketValue":6561000000,"turnoverRate":0.0309,"status":0,"afterMarket":{"amount":20845,"volume":500,"close":41.69,"buyVolume":0,"sellVolume":0,"time":1765524839585,"indexStatus":"Closed 12-12 15:30:00","preClose":40.85},"floatMarketCap":6561000000},"requestUrl":"/m/hq/s/688117","defaultTab":"news","newsList":[{"id":"1116988650","title":"Chengdu Sheng Nuo Biotec (688117.SH): Pentapeptide-18 Approved as New Cosmetic Ingredient","url":"https://stock-news.laohu8.com/highlight/detail?id=1116988650","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116988650?lang=en_us&edition=fundamental","pubTime":"2025-12-03 18:10","pubTimestamp":1764756611,"startTime":"0","endTime":"0","summary":"Chengdu Sheng Nuo Biotec Co.,Ltd. (688117.SH) announced that its wholly-owned subsidiary, Chengdu Kaijie Peptide Technology Co., Ltd., has recently obtained approval from the National Medical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2588728813","title":"Shengnuo Biotec's Two Directors to Dispose of Part of Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2588728813","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588728813?lang=en_us&edition=fundamental","pubTime":"2025-12-01 16:58","pubTimestamp":1764579484,"startTime":"0","endTime":"0","summary":"Two of Chengdu Shengnuo Biotec's  directors plan to dispose of part of their stake in the company to finance personal needs, according to a Shanghai bourse filing on Monday.Deputy General Manager Ma Zhonggang and Chief Financial Officer Wu Li, who's also a deputy general manager, will each offload 18,816 shares, or 0.0120% of the company's total shares, within three months.Currently, Ma owns 175,616 shares, representing 0.1116% of the company's total share capital, while Wu holds 116,816 shares, or 0.0742%.The peptide drug manufacturer's shares dropped over 3% at the close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2584915226","title":"Chengdu Sheng Nuo Biotec  Says Unit Receives Approval From Chinese Medical Regulator for Its Visepegenatide to Enter Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2584915226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584915226?lang=en_us&edition=fundamental","pubTime":"2025-11-19 16:07","pubTimestamp":1763539645,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"2584915083","title":"BRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide API","url":"https://stock-news.laohu8.com/highlight/detail?id=2584915083","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584915083?lang=en_us&edition=fundamental","pubTime":"2025-11-19 16:07","pubTimestamp":1763539645,"startTime":"0","endTime":"0","summary":"BRIEF-Chengdu Sheng Nuo Biotec Says Unit Gets Regulatory Approval For Visepegenatide APINov 19  - ChengDu Sheng Nuo Biotec Co Ltd 688117.SS:SAYS UNIT RECEIVES APPROVAL FROM CHINESE MEDICAL REGULATOR FOR ITS VISEPEGENATIDE ACTIVE PHARMACEUTICAL INGREDIENT TO ENTER MARKETSource textFurther company coverage: 688117.SS  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688117","BK0239"],"gpt_icon":0},{"id":"1181325830","title":"Chengdu Sheng Nuo Biotec (688117.SH): Vipadenant API Receives Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1181325830","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181325830?lang=en_us&edition=fundamental","pubTime":"2025-11-19 16:06","pubTimestamp":1763539572,"startTime":"0","endTime":"0","summary":"Chengdu Sheng Nuo Biotec Co., Ltd. (688117.SH) announced that its wholly-owned subsidiary, Chengdu Sheng Nuo Biopharmaceutical Co., Ltd., recently received the \"Chemical Drug Substance Marketing...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2575295131","title":"ChengDu ShengNuo Biotec Forecasts Up to 145% Surge in January-September Attributable Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2575295131","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575295131?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:05","pubTimestamp":1760436353,"startTime":"0","endTime":"0","summary":"ChengDu ShengNuo Biotec  expects a 101% to 145% rise in its attributable profit to between 114.2 million yuan and 139.6 million yuan in the first three quarters from 56.9 million yuan in the year-ago period, according to a Tuesday filing with the Shanghai bourse.The peptide drug manufacturer's upbeat forecast is attributable to growing demand for peptide active pharmaceutical ingredients, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688117","BK0239"],"gpt_icon":0},{"id":"1141250666","title":"August 22 Holdings Changes Summary: China Yangtze Power Increases Holdings, Chengdu Sheng Nuo Biotec and 8 Other Stocks Reduce Holdings (Table)","url":"https://stock-news.laohu8.com/highlight/detail?id=1141250666","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141250666?lang=en_us&edition=fundamental","pubTime":"2025-08-22 22:40","pubTimestamp":1755873637,"startTime":"0","endTime":"0","summary":"According to statistics, on August 22, China Yangtze Power disclosed its increased holdings situation after market close. Eight A-share listed companies, including Dun'an Environment, Jiayuan...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1119993845.HKD","688117","LU0708995583.HKD","LU1720050803.USD","LU1497733557.USD","LU0877626530.USD","LU1048596156.SGD","LU2213484517.USD","LU0516422952.EUR","LU1794554557.SGD","LU1997245177.USD","LU1997245094.SGD","LU1522347837.USD","LU2495084118.USD","BK0196","LU0516422366.SGD","LU0831103253.SGD","LU2289578879.USD","BK0179","LU0516423174.USD","LU1634259391.SGD","LU1064131003.USD","BK0271","LU1580142542.USD","LU0192582467.USD","LU1585245621.USD","LU2148510915.USD","BK0012","LU1781817850.SGD","LU1997244956.HKD","LU0516423091.SGD","LU0823426480.USD","LU1969619763.USD","SG9999001846.SGD","BK0015","LU0320764599.SGD","LU0052750758.USD","LU1497734951.SGD","LU0039217434.USD","LU0821914370.USD","LU0516422440.USD","LU1634259557.SGD","BK0239","BK0175","LU1655091616.SGD","LU1688375341.USD","LU1255011170.USD","LU1328615791.USD","LU1430594728.SGD","LU0188438112.USD","BK0028","BK0183","600900","LU0205439572.USD","LU2399975544.HKD","BK0188","LU1497733631.SGD","LU0898667661.SGD","BK0006","LU2328871848.SGD","BK0010","LU1961090484.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2561427479","title":"Chengdu Sheng Nuo Biotec  Says Shareholders Plan to Unload up to Combined 3.4% Stake in Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2561427479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561427479?lang=en_us&edition=fundamental","pubTime":"2025-08-22 17:26","pubTimestamp":1755854811,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nL4N3UE0LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2561427231","title":"BRIEF-Sheng Nuo Biotec's Shareholders To Unload Stake In Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2561427231","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561427231?lang=en_us&edition=fundamental","pubTime":"2025-08-22 17:26","pubTimestamp":1755854811,"startTime":"0","endTime":"0","summary":"BRIEF-Sheng Nuo Biotec's Shareholders To Unload Stake In CoAug 22 (Reuters) - ChengDu Sheng Nuo Biotec Co Ltd 688117.SS:SAYS SHAREHOLDERS PLAN TO UNLOAD UP TO COMBINED 3.4% STAKE IN COSource textFurther company coverage: 688117.SS (Reporting by Beijing Newsroom) ((Xiuhao.Chen@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nL4N3UE0LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688117"],"gpt_icon":0},{"id":"2548102099","title":"Shengnuo Biotechnology's Unit Gets Registration Certificate for Type 2 Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2548102099","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548102099?lang=en_us&edition=fundamental","pubTime":"2025-07-01 15:15","pubTimestamp":1751354147,"startTime":"0","endTime":"0","summary":"Chengdu Shengnuo Biotechnology's  unit, Chengdu Shengnuo Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its exenatide injection, according to a Shanghai bourse filing on Tuesday.The drug is used to improve glycemic control in patients with type 2 diabetes, particularly in cases where blood glucose remains inadequately controlled with monotherapy using metformin, sulfonylureas, or a combination of metformin and sulfonylureas, the pharmaceutical company said.The company's shares closed less than 5% higher.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688117","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-06-03","address":"四川省成都市大邑县大安路98号","stockEarnings":[{"period":"1week","weight":0.0294},{"period":"1month","weight":0.0762},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.2609},{"period":"1year","weight":0.9449},{"period":"ytd","weight":1.282}],"companyName":"成都圣诺生物科技股份有限公司","boardCode":"AI0027","perCapita":"15626股","boardName":"医药制造业","registeredCapital":"15738万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售，同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。","serverTime":1765689318958,"listedPrice":17.9,"stockholders":"10072人(较上一季度减少9.53%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Chengdu Sheng Nuo Biotec Co.,Ltd.(688117),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Chengdu Sheng Nuo Biotec Co.,Ltd.(688117) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Chengdu Sheng Nuo Biotec Co.,Ltd.,688117,Chengdu Sheng Nuo Biotec Co.,Ltd.股票,Chengdu Sheng Nuo Biotec Co.,Ltd.股票老虎,Chengdu Sheng Nuo Biotec Co.,Ltd.股票老虎国际,Chengdu Sheng Nuo Biotec Co.,Ltd.行情,Chengdu Sheng Nuo Biotec Co.,Ltd.股票行情,Chengdu Sheng Nuo Biotec Co.,Ltd.股价,Chengdu Sheng Nuo Biotec Co.,Ltd.股市,Chengdu Sheng Nuo Biotec Co.,Ltd.股票价格,Chengdu Sheng Nuo Biotec Co.,Ltd.股票交易,Chengdu Sheng Nuo Biotec Co.,Ltd.股票购买,Chengdu Sheng Nuo Biotec Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Chengdu Sheng Nuo Biotec Co.,Ltd.(688117),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Chengdu Sheng Nuo Biotec Co.,Ltd.(688117) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction